ACIST Medical Systems, Inc. (“ACIST”) shares its heartfelt empathy with the communities impacted worldwide by COVID-19. As the world responds to this pandemic, we remain committed to supporting you to ensure that the vital work of delivering new therapies to patients continues.
At ACIST, we are taking precautions to protect the health and safety of our employees and their families, our customers, patients and communities. Click here to view our full response to how we are handling COVID-19 and product specific cleaning letters.
Clinical studies on the short and long-term impact of COVID-19 are being published daily. There is a large body of clinical evidence published on COVID-19 and kidney health. The following is a summary based on a review of the publications cited by the National Kidney Foundation, CDC, and other professional societies.
A meta-analysis of over 30 studies demonstrates that COVID-19 istough on organs, including kidneys.1
Acute kidney injury (AKI)has been observed in COVID-19 patients, even among non-elderly, otherwise healthy adults.2
Among COVID-19 patients, there is astrong correlation between cardiac injury and kidney injury.3
AKI is strongly correlated to severity and mortality3 in COVID-19 patients.1,4,5
AKI is present in up to 30% of hospitalized patients and it is uncertain how many will regain their kidney function.6 According to the National Kidney Foundation, after COVID-19 recovery, these patients are at increased risk of developing Chronic Kidney Disease.2
Before COVID-19, ~30% of patients presenting for coronary angiography procedures were at risk for post-procedure CI-AKI.7
With the impact of COVID-19, this population may increase, as COVID-19 survivors who experienced AKI or blood and/or protein in their urine are at an elevated risk of developing chronic kidney disease.2
ACIST CVi can help reduce and track contrast delivery during angiography procedures, reducing the potential risk for CI-AKI compared to hand manifold.9
9. Minsinger KD, Kassis HM, Block CA, Sidhu M, Brown JR (2014) Meta-analysis of the effect of automated contrast injection devices versus manual injection and contrast volume on risk of contrast-induced nephropathy. Am J Cardiol 113 (1): 49-53.
Learn more about how ACIST Medical Systems is responding to the pandemic.
Receive guidance on how to clean the CVi System.
Receive guidance on how to clean the HDi System.
Receive guidance on how to clean the RXi System.
© 2022 ACIST Medical Systems. All rights reserved.
Contact a rep to learn more about ACIST CVi.